Acorda Buys Neurology Drug Developer Civitas Ahead Of IPO
This article was originally published in The Pink Sheet Daily
Acorda gains an inhalable dry-powder version of levodopa, which it plans to move into a Phase III trial for the treatment of Parkinson’s disease in 2015, in exchange for $525 million in cash.
You may also be interested in...
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.